Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 11
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/1/2007
 
First Published:
10/1/1999
1.
Phase II/III Randomized Study of Leflunomide (SU101) With Mitoxantrone and Prednisone Versus Mitoxantrone and Prednisone Alone in Patients With Hormone Refractory Prostate Cancer (Summary Last Modified 01/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.035
SUGEN-990711, NCT00004071
Last Modified:
5/17/2007
 
First Published:
6/1/1998
2.
Phase III Randomized Study of Leflunomide (SU101) Versus Procarbazine for Patients with Glioblastoma Multiforme in First Relapse (Summary Last Modified 01/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.015
MSKCC-98020, UCLA-HSPC-980105201, NCT00003293
Last Modified:
7/1/1997
3.
Phase I/II Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) in Ovarian Cancer, non-Small Cell Lung Cancer, and Prostate Cancer (Summary Last Modified 07/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.004
NCI-V96-1091
Last Modified:
11/1/1999
 
First Published:
9/1/1998
4.
Phase II Study of Leflunomide (SU101) in Patients with Recurrent Stage III or IV Ovarian Cancer (Summary Last Modified 11/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.009
NYU-9828
Last Modified:
9/1/1999
 
First Published:
2/1/1999
5.
Phase II Study of Leflunomide (SU101) in Patients with Advanced Non-Small Cell Lung Cancer (Summary Last Modified 09/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.010
Last Modified:
5/1/2000
 
First Published:
4/1/1999
6.
Phase II Study of Leflunomide (SU101) in Patients with Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma in First Relapse (Summary Last Modified 05/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
SUGEN-SU101.021
MSKCC-98111, NCI-G99-1506, NCT00003775
Last Modified:
7/1/1997
7.
Phase I Study of SU101 Administered by Four Weekly 24-Hour Infusions for Recurrent Malignant Gliomas (Summary Last Modified 07/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
MSKCC-95019
NCI-V95-0663
Last Modified:
8/1/1997
8.
Phase I Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) in Advanced Solid Malignancies (Summary Last Modified 08/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.002
NCI-V96-1090
Last Modified:
12/1/1997
9.
Phase I Study of SU101 (a Platelet-Derived Growth Factor Receptor Inhibitor) Given Weekly Following a Loading Dose in Advanced Solid Malignancies (Summary Last Modified 12/97)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
SUGEN-SU101.003
NCI-V96-1092
Last Modified:
8/1/2000
10.
Phase I Study of Leflunomide (SU101) in Pediatric Patients with Refractory Malignancy (Summary Last Modified 08/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
3 to 21
NCI, Pharmaceutical / Industry
NCI-97-C-0087E
SUGEN-NCI-97-C-0087
Select All on One Page
1
2
Next >
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute